glp3.wiki
Approval status varies by treatment

Editorially reviewed · Last updated September 8, 2026 · How we review

Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist

Part of Weight Loss Drug Comparison Index.

Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist — What the Data Actually Says

There is no validated human dosing protocol for cagrilintide with tirzepatide in the sources reviewed here. The direct combination evidence is a short rat experiment. Trials of CagriSema test cagrilintide with semaglutide, so they cannot supply a dosing schedule for adding it to tirzepatide.

Cagrilintide remains investigational, and FDA says it cannot be used in compounding under federal law. This page separates the biological rationale from what has actually been tested, including why a plateau does not establish that adding another compound will help.

What Each Drug Does

Tirzepatide (Mounjaro/Zepbound)Cagrilintide
Drug classDual incretin agonistLong-acting amylin analog
ReceptorsGLP-1 + GIPAmylin (AMY1R, AMY3R) + Calcitonin
ManufacturerEli LillyNovo Nordisk
FDA statusApproved (Mounjaro 2022, Zepbound 2023)Not approved (NDA filed as part of CagriSema, Dec 2025)
DosingOnce weekly injection, 2.5-15 mgOnce weekly injection (studied at 0.3-4.5 mg in trials)
Selected trial resultsSee direct REDEFINE 4 comparison below11.8% as monotherapy in REDEFINE 1, 68 weeks, efficacy estimand
Primary side effectsNausea, diarrhea, constipationGastrointestinal events; combination tolerability is not established

Tirzepatide activates GLP-1 and GIP receptors; cagrilintide targets amylin/calcitonin receptors. Distinct receptors provide a rationale for research, but their downstream effects on appetite can overlap. Receptor counting does not establish added benefit or safety.

Why People Are Combining Them

The practical question is whether adding a second agent could help when weight loss or appetite suppression has plateaued. That remains unproven for cagrilintide plus tirzepatide.

A 2025 Nature Medicine case study recorded brain activity in one participant with severe, treatment-resistant obesity and food preoccupation while taking tirzepatide. Severe food preoccupation returned during follow-up despite treatment. The report does not establish a general five-month tolerance rule, show that the entire reward center “went silent,” or test an amylin add-on.
CagriSema research shows that cagrilintide can contribute to a semaglutide combination under a trial protocol. Applying that result to tirzepatide requires separate human evidence.

Published Evidence for the Combination

Preclinical Data: ADA 2024

The direct evidence retrieved for this combination is ADA 2024 conference abstract 300-OR: a 12-day study in diet-induced obese male rats, dosed subcutaneously once daily. The weight changes below are relative to vehicle, not human baseline weight loss:
TreatmentWeight difference versus vehicle (12 days)Notes
Cagrilintide 3 nmol/kg-7.2%Amylin agonist alone
Cagrilintide 10 nmol/kg-9.6%Higher dose
Tirzepatide 3 nmol/kg-2.5%Dual incretin alone
Tirzepatide 10 nmol/kg-5.8%Higher dose
Combination (3 + 3 nmol/kg)-11.0%Greater reduction than either monotherapy at the same 3 nmol/kg dose

The abstract reports a statistically greater weight reduction with the combination than either drug at the same 3 nmol/kg dose. It also reports greater ALT reductions and lower triglycerides than the tirzepatide group. It does not establish a human dose or prove pharmacologic synergy.

However, this was a 12-day study in diet-induced obese rats — not humans.

CagriSema vs Tirzepatide: REDEFINE 4 (February 2026)

The closest human evidence comes from REDEFINE 4, Novo Nordisk's head-to-head trial comparing CagriSema (cagrilintide + semaglutide) against tirzepatide:

CagriSema 2.4/2.4 mgTirzepatide 15 mg
Weight loss (efficacy estimand)-23.0%-25.5%
Weight loss (treatment-regimen estimand)-20.2%-23.6%
Primary endpointDid not demonstrate non-inferiorityComparator
Duration84 weeks84 weeks
Participants809 total
CagriSema did not meet the non-inferiority endpoint. This was an open-label comparison of two treatments, not a study adding cagrilintide to tirzepatide. It therefore cannot answer whether that add-on would help, fail or cause more adverse effects. The efficacy estimand assumes treatment adherence; the treatment-regimen estimand estimates effects regardless of adherence.

Eli Lilly's Answer: Eloralintide + Tirzepatide

Eli Lilly is developing its own amylin agonist, eloralintide, and has studied it with tirzepatide in the Phase 2 trial NCT06603571. The current record lists primary completion on July 1, 2026, active/not-recruiting status and no posted results. This trial has nine treatment arms plus placebo, in adults with overweight or obesity and type 2 diabetes, with a primary endpoint of weight change at 48 weeks.

Eloralintide monotherapy had the following Phase 2 efficacy-estimand results. These are not results of cagrilintide or of an add-on regimen:

DoseWeight Loss (48 weeks)
Eloralintide 1 mg-9.5%
Eloralintide 3 mg-12.4%
Eloralintide 6 mg-17.6%
Eloralintide 9 mg-20.1%
Placebo-0.4%

Eloralintide is a different molecule from cagrilintide. Its monotherapy findings and combination-development program cannot validate a cagrilintide–tirzepatide dosing schedule.

Safety Concerns

There is no established human safety profile for the specific cagrilintide–tirzepatide combination in the evidence retrieved for this review. The rat experiment cannot quantify gastrointestinal symptoms, interactions or longer-term risks in people.

Gastrointestinal effects are relevant to amylin/incretin treatment, but claims that this particular combination causes a defined “additive gastroparesis risk” or a predictable degree of muscle loss go beyond the available data. Unknown risk should remain unknown, rather than being presented as either safety or a measured harm.

FDA says cagrilintide cannot be used in compounding under federal law. A clinician's involvement or a seller's “research” label does not turn an unapproved product into an approved combination treatment.

Where Retatrutide Fits

Retatrutide activates GLP-1, GIP and glucagon receptors in one molecule. It does not add amylin receptor agonism. Its Phase 3 program supplies human efficacy and safety evidence, but it remains investigational; Lilly plans a BLA submission in Q1 2027.

There is no direct comparison with cagrilintide plus tirzepatide. TRIUMPH-4's 28.7% mean weight loss at 12 mg at week 68 is an efficacy-estimand result in adults with obesity or overweight and knee osteoarthritis. Comparing that number with REDEFINE 4 cannot establish which approach is better.

The energy-expenditure effect attributed to retatrutide was demonstrated in preclinical research; its contribution to human weight loss is not established by these percentages. One molecule also does not, by itself, prove lower risk than two.

For the separate CagriSema comparison, see Retatrutide vs CagriSema.

Frequently Asked Questions

Can you take cagrilintide and tirzepatide together?

The retrieved evidence does not establish a safe or effective human regimen. The direct combination study was in rats. CagriSema and eloralintide studies concern different combinations, and FDA says cagrilintide cannot be used in compounding under federal law.

What is the cagrilintide dosage with tirzepatide?

No validated human schedule is established in the evidence reviewed here. Doses studied with semaglutide or in rats cannot be converted into a cagrilintide–tirzepatide protocol. Do not treat either as instructions for self-dosing.

Is cagrilintide the same as CagriSema?

No. Cagrilintide is one of the two components of CagriSema. CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (2.4 mg, an amylin analog) and semaglutide (2.4 mg, a GLP-1 agonist) in a single once-weekly injection. Cagrilintide alone is not FDA-approved for any indication.

Did CagriSema beat tirzepatide in the head-to-head trial?

No. In REDEFINE 4 (results announced February 23, 2026), CagriSema achieved 23.0% weight loss versus tirzepatide's 25.5% at 84 weeks. CagriSema failed to demonstrate non-inferiority to tirzepatide. REDEFINE 11 studies CagriSema 2.4/2.4 mg; Novo has started a separate higher-dose study.

Is retatrutide better than cagrilintide plus tirzepatide?

No direct comparison establishes that. Retatrutide has human Phase 3 data, but the retrieved cagrilintide–tirzepatide evidence does not supply a human comparator. Different receptor targets and separate-trial percentages cannot establish superiority.

What is eloralintide?

Eloralintide is Eli Lilly's investigational amylin receptor agonist (previously LY3841136). In Phase 2, it achieved up to 20.1% weight loss as monotherapy at 48 weeks. Lilly is currently studying it in combination with tirzepatide in a Phase 2 trial (NCT06603571) for adults with obesity and type 2 diabetes. The Phase 2 combination registry lists primary completion in July 2026 and no posted results at this review.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Tirzepatide is FDA-approved for specific indications under the Mounjaro and Zepbound brands. Cagrilintide is investigational; combining it with tirzepatide is not an FDA-approved treatment.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →